Gastric vs Transpyloric Feeding for Bronchopulmonary Dysplasia
Trial Summary
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Gastric feeding, Transpyloric feeding for Bronchopulmonary Dysplasia?
Research shows that feeding into the small bowel (transpyloric feeding) is often recommended to improve nutrient delivery for critically ill patients, which might help reduce complications. However, studies have not consistently shown clear benefits of transpyloric feeding over gastric feeding in terms of growth or reducing complications in infants, and current evidence does not support routine use of transpyloric feeding in critically ill patients.12345
Is transpyloric feeding safe for infants?
Transpyloric feeding in infants, especially those with low birth weight, has been associated with more complications compared to other feeding methods like nasogastric feeding. While it may offer some benefits like reduced risk of aspiration (breathing in food or liquid) and faster weight gain, it also involves greater risks and costs, making it less recommended as a routine feeding method.23678
How does gastric vs transpyloric feeding treatment differ for bronchopulmonary dysplasia?
Gastric and transpyloric feeding differ in the route of administration; gastric feeding delivers nutrients directly to the stomach, while transpyloric feeding bypasses the stomach and delivers nutrients directly to the small intestine. This can be beneficial in reducing the risk of aspiration (inhaling food into the lungs) and may lead to more rapid weight gain in preterm infants, although it may also come with more complications.12679
What is the purpose of this trial?
Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.
Research Team
Mark Weems, MD
Principal Investigator
University of Tennessee
Eligibility Criteria
This trial is for hospitalized infants with severe bronchopulmonary dysplasia (BPD) who are experiencing feeding intolerance. The study requires a crossover, meaning each infant will try both feeding methods for two weeks each.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to 2 weeks of continuous gastric feeding or continuous transpyloric feeding, followed by a crossover to the other feeding mode for an additional 4 weeks.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Gastric feeding
- Transpyloric feeding
Find a Clinic Near You
Who Is Running the Clinical Trial?
Le Bonheur Children's Hospital
Lead Sponsor